Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

BACKGROUND: Tumour necrosis factor alpha (TNFα)‐antagonism effectively treats ulcerative colitis (UC). The golimumab clinical programme evaluated subcutaneous (SC) and intravenous (IV) induction, and SC maintenance regimens, in TNFα‐antagonist‐naïve patients with moderate‐to‐severe active UC despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutgeerts, P., Feagan, B. G., Marano, C. W., Padgett, L., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Zhang, H., Colombel, J.‐F., Reinisch, W., Gibson, P. R., Sandborn, W. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Randomised Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755132/
https://www.ncbi.nlm.nih.gov/pubmed/26119226
http://dx.doi.org/10.1111/apt.13291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755132/
https://www.ncbi.nlm.nih.gov/pubmed/26119226
http://dx.doi.org/10.1111/apt.13291

Ejemplares similares